Crossmark Global Holdings Inc. raised its stake in shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) by 2.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,964 shares of the medical equipment provider’s stock after buying an additional 526 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Zimmer Biomet were worth $2,288,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. QCI Asset Management Inc. NY raised its stake in Zimmer Biomet by 2.0% during the fourth quarter. QCI Asset Management Inc. NY now owns 135,216 shares of the medical equipment provider’s stock valued at $16,317,000 after buying an additional 2,712 shares during the last quarter. WASHINGTON TRUST Co raised its stake in Zimmer Biomet by 4.1% during the fourth quarter. WASHINGTON TRUST Co now owns 92,812 shares of the medical equipment provider’s stock valued at $11,199,000 after buying an additional 3,659 shares during the last quarter. Exchange Capital Management Inc. increased its holdings in shares of Zimmer Biomet by 26.1% in the 4th quarter. Exchange Capital Management Inc. now owns 6,479 shares of the medical equipment provider’s stock worth $782,000 after purchasing an additional 1,343 shares in the last quarter. Stephens Inc. AR increased its holdings in shares of Zimmer Biomet by 6.8% in the 4th quarter. Stephens Inc. AR now owns 41,637 shares of the medical equipment provider’s stock worth $5,024,000 after purchasing an additional 2,646 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Zimmer Biomet by 14.7% in the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock worth $576,488,000 after purchasing an additional 612,044 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $116.39 on Monday. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. Zimmer Biomet Holdings Inc has a fifty-two week low of $108.03 and a fifty-two week high of $133.49. The company has a market capitalization of $23,565.83, a price-to-earnings ratio of 12.92, a P/E/G ratio of 2.04 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $2.10. Zimmer Biomet had a return on equity of 15.45% and a net margin of 23.51%. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter in the previous year, the company posted $2.14 earnings per share. Zimmer Biomet’s revenue was up 3.0% compared to the same quarter last year. analysts forecast that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. The ex-dividend date was Thursday, December 28th. Zimmer Biomet’s payout ratio is currently 10.65%.

A number of analysts have commented on the company. Cantor Fitzgerald reissued a “buy” rating and issued a $140.00 target price on shares of Zimmer Biomet in a report on Monday, February 5th. BMO Capital Markets reissued a “buy” rating and issued a $144.00 target price on shares of Zimmer Biomet in a report on Tuesday, January 30th. Leerink Swann lifted their target price on Zimmer Biomet from $142.00 to $146.00 and gave the stock an “outperform” rating in a report on Wednesday, January 31st. Stifel Nicolaus raised Zimmer Biomet from a “hold” rating to a “buy” rating and lifted their target price for the stock from $120.00 to $168.00 in a report on Wednesday, January 31st. Finally, Robert W. Baird reissued a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, January 31st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $141.67.

ILLEGAL ACTIVITY NOTICE: “Crossmark Global Holdings Inc. Buys 526 Shares of Zimmer Biomet Holdings Inc (ZBH)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2018/02/12/crossmark-global-holdings-inc-buys-526-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.